Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

Complement System

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of immunotherapy on seizure severity and spike-wave index in epileptic encephalopathy with spike-wave activation in sleep: The value of EEG spikes in monitoring treatment response.

Epilepsy research·2026

Same author

Impact of Intravenous Immunoglobulin on Neuroinflammation Markers in Patients With Electrical Status Epilepticus During Slow Sleep.

In vivo (Athens, Greece)·2026

Same author

[Increased serum transferrin receptor 1 levels are associated with severity of acute ischemic stroke in patients with Covid-19 pneumonia].

Ideggyogyaszati szemle·2026

Same author

Immune-driven mechanisms in idiopathic intracranial hypertension: a critical synthesis.

Reviews in the neurosciences·2026

Same author

NLRP3 and RANK-RANKL-OPG Pathway-related Gene Expression Levels in Children With Autism Spectrum Disorder.

In vivo (Athens, Greece)·2026

Same author

Aquaporin-1 Antibodies in Autoimmune Inflammatory Demyelinating Disorders with Predominant Optic Nerve & Spinal Cord Involvement.

Noro psikiyatri arsivi·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.

Premkumar Christadoss¹, Erdem Tüzün, Jing Li

¹Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555-1070, USA. pchrista@utmb.edu

Annals of the New York Academy of Sciences

|June 24, 2008

Summary

Blocking the classical complement pathway (CCP) and interleukin-6 (IL-6) shows promise for treating myasthenia gravis (MG). Targeting CCP factors like C1q, C2, or C4 may offer effective therapeutic strategies for MG.

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Related Experiment Videos

Last Updated: Jul 4, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Area of Science:

Immunology
Neuroimmunology
Complement System Biology

Background:

Experimental autoimmune myasthenia gravis (EAMG) severity is linked to complement factors.
Mice lacking complement factors C3, C4, or C5 exhibit resistance to EAMG.
Interleukin-6 (IL-6) and complement factor C3 levels are interdependent in EAMG pathogenesis.

Purpose of the Study:

To investigate the role of the classical complement pathway (CCP) and IL-6 in EAMG.
To evaluate the therapeutic potential of blocking CCP activation and/or IL-6 for MG treatment.
To explore the use of anti-C1q antibodies in suppressing EAMG.

Main Methods:

Utilized mice deficient in complement factors (C3, C4, C5) and IL-6-deficient mice.
Administered anti-C1q antibodies pre- and post-immunization with acetylcholine receptor (AChR).
Assessed EAMG severity, IL-6 production by lymph node cells (LNCs), and immune complex deposition.

Main Results:

Anti-C1q antibody treatment suppressed EAMG, reduced LNC IL-6 production, and decreased immune deposits at neuromuscular junctions.
Low-dose anti-C1q antibody treatment improved clinical EAMG severity and reduced LNC IL-6.
Circulating immune complex (CIC) levels correlated with EAMG severity, driven by FCgammaR interaction.

Conclusions:

Blocking CCP activation, specifically targeting C1q, C2, or C4, is a potential therapeutic strategy for MG.
Combined inhibition of CCP factors and IL-6 could offer tailored MG therapies.
Preserving the alternate complement pathway while inhibiting CCP is feasible with targeted therapies.